|
Apr 12
|
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
|
|
Mar 26
|
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
|
|
Mar 11
|
PRTG: Extending the Runway
|
|
Nov 28
|
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
|
|
Sep 5
|
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors
|